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Clinical treatment trials are increasingly being designed in primary mitochondrial disease
(PMD), a phenotypically and genetically heterogeneous collection of inherited multi- system
energy deficiency disorders that lack effective therapy. We sought to identify motivating fac-
tors and barriers to clinical trial participation in PMD.
Methods
A survey study was conducted in two independent mitochondrial disease subject cohorts. A
discovery cohort invited subjects with well-defined biochemical or molecularly- confirmed
PMD followed at a single medical center (CHOP, n = 30/67 (45%) respondents). A replica-
tion cohort included self-identified PMD subjects in the Rare Disease Clinical Research Net-
work (RDCRN) national contact registry (n = 290/1119 (26%) respondents). Five-point
Likert scale responses were analyzed using descriptive and quantitative statistics. Experi-
enced and prioritized symptoms for trial participation, and patient attitudes toward detailed
aspects of clinical trial drug features and study design.
Results
PMD subjects experienced an average of 16 symptoms. Muscle weakness, chronic
fatigue, and exercise intolerance were the lead symptoms encouraging trial participation.
Motivating trial design factors included a self-administered study drug; vitamin, antioxi-
dant, natural or plant-derivative; pills; daily treatment; guaranteed treatment access during
and after study; short travel distances; and late-stage (phase 3) participation. Relative trial
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participation barriers included a new study drug; discontinuation of current medications; dis-
ease progression; daily phlebotomy; and requiring participant payment. Treatment trial type
or design preferences were not influenced by population age (pediatric versus adult), prior
research trial experience, or disease severity.
Conclusions
These data are the first to convey clear PMD subject preferences and priorities to enable
improved clinical treatment trial design that cuts across the complex diversity of disease.
Partnering with rare disease patient communities is essential to effectively design robust
clinical trials that engage patients and enable meaningful evaluation of emerging treatment
interventions.
Introduction
Dramatic advances in genomic sequencing technologies have enabled marked improvements
in the diagnosis and mechanistic understanding of primary mitochondrial disease (PMD).
PMD is a highly heterogeneous collection of energy deficiency disorders, which are now recog-
nized to result from more than 250 different gene disorders that can originate in either the
nuclear DNA or mitochondrial DNA genome [1]. PMD are characterized by extensive clinical
variability, with often progressive organ dysfunction occurring in nearly any system at any
age. Collectively, PMD comprise the most common inborn error of metabolism but remain a
rare disease, with minimal prevalence estimated at 1 in 4,300 individuals [2]. No FDA-
approved treatments exist for mitochondrial disease, despite the first clinical trial for mito-
chondrial disease having been conducted in 1990 [3]. Two decades later, a systematic meta-
analysis identified only 12 methodologically robust clinical trials, which yielded no efficacious
evidence [4]. Hence, the vast majority of treatments used in mitochondrial disease patients are
given on an empiric basis without having been objectively evaluated in robust clinical trials [5–
9]. Current clinical practice for treating mitochondrial disease patients is therefore largely
based upon clinical experience, small open label studies, case reports, and anecdotal evidence
[5, 10, 11].
Rare disorders, such as PMD, are well-recognized to impose a distinct set of challenges in
the classic clinical research infrastructure that do not easily fit into trial designs for common
complex diseases [12–17]. Specific to PMD, each molecular subtype typically has very low
prevalence with an increasing array of causal etiologies recognized, leading to a nearly four-
fold increase in the number of disease-causing genes known to cause PMD over the last
decade [1, 18, 19]. Given this inherent disease heterogeneity and rapidly changing diagnostic
capabilities, their mechanistic basis and potential treatment approaches are only now being
effectively deciphered [20]. Natural histories of many PMD subtypes has been lacking,
although is increasingly prioritized for systematic study, such as through collaborative multi-
site national initiatives including the NIH Rare Disease Clinical Research Network (RDCRN)
in the North American Mitochondrial Disease Consortium (NAMDC, https://www.
rarediseasesnetwork.org/cms/NAMDC). Establishment of multi-site national disease registries
can further facilitate multi-center trial networks, which are ultimately necessary to enroll suffi-
cient subjects with a given disease etiology or subtype in rare disease [21, 22].
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However, the inherent clinical complexity of multi-system disorders such as PMD pose a
substantial challenge to ready identification and prioritization of appropriate clinical trial end-
point(s) and validated outcome measures [23–28]. Trial design characteristics have been chal-
lenging to standardize in PMD, including standard-of-care treatment regimen determination,
study duration period, placebo-control, blinding, and randomization. Additional trial design
challenges previously reported in in PMD have included subject recruitment and retainment
[6], subject hesitation to discontinue current medications and dietary supplements [8, 28],
travel barrier to study sites [6] and fear of potential adverse consequences [6, 9]. As such,
many of the trials that have been designed in the past were based on investigator and/or phar-
maceutical sponsor prioritized outcomes and trial design characteristics without widespread
upfront engagement of the PMD patient perspective to inform them.
The nexus of improving PMD etiology and mechanistic understanding, appreciation for
alternative trial designs for rare disease [29, 30] and a growing cadre of pharmaceutical
research in new therapeutic targets for mitochondrial disease have brought renewed focus on
the emerging potential to realize effective therapies for mitochondrial disease [28]. However,
the success of this effort is contingent on successfully identifying PMD subject motivations
and barriers to participate in clinical treatment trials. Here, we report results of an electronic
survey designed to explore the patient perspective on these complex issues in exploratory and
validation PMD cohorts, with substantial insights evident to improve clinical trial design in
PMD.
Methods
Study design and PMD cohorts description
We designed and conducted an online electronic survey to determine the motivations and bar-
riers to participate in clinical trials in adult and pediatric PMD patients, which consisted of
questions divided into five key domains: Demographics, Symptom checklist of 35 options,
Drug therapy, Study Design, and Additional Study Design Factors (S1 File). A few questions
were developed to assess the validity of the responses. For analysis of patient attitudes toward
clinical trial study design, subjects were asked if they would participate if half of the people
receive placebo and the other half receive active drug, and asked separately if they would par-
ticipate if half of the people get the active drug while the other half receive placebo. Given this
is the same question, all subjects did respond identically for both questions. The initial survey
was administered January through March 2014 in Research Electronic Data Capture (RED-
Cap) to 67 invited subjects and families with definite or suspected mitochondrial disease
enrolled in a Children’s Hospital of Philadelphia (CHOP) institutional review board approved
study #08–6177 (MJF, PI) after providing written consent. Informed consent was obtained
from parents/guardians of subjects <18 years of age. PMD subjects were defined as ‘definite’
when their molecular etiology was confirmed, and ‘suspected’ based only upon biochemical
and/or clinical evidence. All returned surveys were anonymous to the study team, with diag-
nostic confirmation possible through cross-referencing gender, age, and zip code with the
study database. Parents were asked to complete the survey on behalf of affected children, with
a separate survey response completed on their own behalf if the parent themselves were also
affected with PMD. The same online survey instrument was administered June through
November 2014 via the RDCRN Data Management and Coordinating Center (DMCC)
Oracle Database to a validation cohort of self-identified PMD subjects, and administered fol-
lowing a CHOP IRB waiver and RDCRN approval with mass-cohort email blast to 1,119 PMD
subjects on two occasions. All ages were eligible to participate, where primary caregivers were
requested to complete the survey for dependents. Inclusion criteria included definite or
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suspected mitochondrial disease, fluency in English and internet access. Incomplete surveys
were excluded from analysis. Survey questions were closed-ended with responses along a
5-point Likert scale. Survey data was captured in REDCap for the initial CHOP-based PMD
survey and in the Oracle Database for the validation RDCRN PMD survey.
Statistical analyses
Affirmative responses were interpreted along a 5-point Likert scale of severity ranging from
‘most’ to ‘mild’ in the symptoms domain, and as ‘likely to participate’ and ‘would participate’
in all other categories. Results were prepared as tabulated descriptive statistics and presented
as numbers (n) and percentage (%) of total respondents per question. A cohort-wide willing-
ness to participate threshold 80% was considered to be clinically significant for evaluation of
an individual item. Subgroup analysis of participants who completed the survey on behalf of
themselves (18 years, adult), and participants who completed the survey on behalf of affected
dependents (child) was not performed in the CHOP cohort due to small sample size, but was
completed in the RDCRN validation survey (total respondents, n = 169 adults and n = 121
children). Chi-squared test was used to compare responses in the subgroup analysis. Logistic
regression analysis was used to test the effect of having past experience in clinical research par-
ticipation (n = 124) on the willingness to participate in a clinical trial. The Wilcoxon rank-sum
test was used to analyze the association between subject PMD disease severity and permissible
treatment burden (n = 263). All statistical analyses were performed with SAS 6.1 or higher
(SAS Institute Inc, Cary, NC). P value< 0.05 was claimed to be statistically significant.
Results
Demographic factors and symptoms
In the CHOP-based exploratory PMD cohort survey, a 45% respondent rate was obtained (30
of 67 invited participants with definite or suspected PMD). Demographic details are summa-
rized in Table 1, with equal numbers of pediatric (n = 15) and adult (n = 15) PMD subject
respondents. All subjects had definite or suspected PMD. Among the 35 symptom option
selections, CHOP PMD subjects (n = 30) reported 16.3 ± 5.6 (mean ±SD, range 6–28) symp-
toms. Fig 1A and Part A of S1 Table detail the most commonly experienced symptoms, where
the top 5 include: (1) muscle weakness, (2) chronic fatigue, (3) exercise intolerance; (4) imbal-
ance, and (5) gastrointestinal problems. Specifically within the pediatric PMD subject cohort,
however, developmental delay replaced gastrointestinal problems in the top 5 most common
symptoms. When asked which symptom(s) would encourage trial participation, the same 5
prioritized symptoms were listed, including developmental delay in children (Fig 1B and Part
B of S1 Table). When asked to select the top 3 symptoms each subject would prioritize for trial
participation, muscle weakness, chronic fatigue, and exercise intolerance were ranked among
the highest across the cohort. In the pediatric- specific subset, however, the top 3 prioritized
symptoms for clinical trial participation included developmental delay, muscle weakness, and
epilepsy (Part D of S1 Table). Targeted analysis of willingness to participate in a clinical trial
only among those respondents who experience that particular symptom is shown in Fig 1C
and Part C of S1 Table. Notably, this analysis revealed that all PMD subjects who have experi-
enced muscle weakness (n = 27), peripheral neuropathy (n = 13), tinnitus (n = 7), diabetes
(n = 4), and stroke (n = 3) would participate in a clinical trial that targeted these symptoms.
Additionally, in the child group, all subjects with developmental delay (n = 14), learning dis-
ability (n = 10) and dysautonomia (n = 4) would participate in a trial.
In the RDCRN survey PMD validation cohort, a 26% response rate was obtained (298 of
1,119 RDCRN-enrolled invited participants). Eight responses were incomplete and excluded
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Table 1. Demographic and other key characteristics of the CHOP patient cohort (N = 30).
Adults (n = 15) Children (n = 15) p-value1
Gender, Female—% (n) 46.7 (7) 53.3 (8) 1.0
Age, years: median (IQR) 22–73 (46) 0.5–17 (7) <.0001
Diagnostic certainty–% (n) 1.0
Definite 46.6 (7) 26.6 (4)
Suspected 53.3 (8) 73.3 (11)
Adults and Children (n = 30)
Highest Education % (n)
Less than high school degree 0 (0)
High school degree or equivalent 13 (4)
Some college but no degree 27 (8)
Associate degree 3 (1)
Bachelor degree 17 (5)




Have participated in a previous research study 69 (20)
Have participated in a clinical trial 34 (10)
Know someone who participated in a clinical trial 41 (12)
1Comparison by two-sample t-test between Adult and Child groups is indicated by p-value
https://doi.org/10.1371/journal.pone.0197513.t001
Fig 1. CHOP mitochondrial disease subject discovery cohort. A. Experienced Symptoms. The CHOP PMD subject cohort reported muscle weakness, chronic
fatigue, exercise intolerance, imbalance, and gastrointestinal problems as the top 5 most commonly experienced symptoms (n = 30). B. Prioritized Symptoms for trial
participation. The CHOP PMD patient cohort reported the top 5 most commonly experienced symptoms as the same leading symptoms to motivate their trial
participation (n = 30). C. Likely to participate if experienced symptom is targeted in a clinical trial. All CHOP PMD subjects who experienced muscle weakness
(n = 37), peripheral neuropathy (n = 13), tinnitus (n = 7), diabetes (n = 4), and stroke (n = 3) reported they would participate in a clinical trial that targeted these
symptoms.
https://doi.org/10.1371/journal.pone.0197513.g001
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from analysis. Demographic details are summarized in Table 2, with n = 169 adults and
n = 121 parents completing the survey for their children among the PMD subject respon-
dents. In this self-reported PMD cohort, 40.7% of subjects reported having a definite molec-
ular diagnosis, of whom 37.2% reported having mitochondrial DNA mutations. Identical to
what was reported in the CHOP PMD cohort, RDCRN cohort subjects reported 15.6 ± 5.9
(mean ±SD, range 2–30) symptoms. The 5 most commonly experienced and 5 most priori-
tized symptoms for clinical trial participation were also identical to those identified in the
CHOP PMD cohort survey (Fig 2A–2C and Parts A-D of S2 Table). Interestingly among
the affirmative responses, ‘exercise intolerance’ was identified among the RDCRN cohort as
the leading symptom in the ‘most severe’ category in all subjects and in the adult group
(n = 169), as well as the second leading symptom after developmental delay in the pediatric
group (n = 121) (S3 Table). The top 3 experienced symptoms that would encourage trial par-
ticipation in adults (n = 169) were the same symptoms seen in the CHOP PMD cohort of
chronic fatigue, muscle weakness and exercise intolerance although in the pediatric cohort
(n = 121) exercise intolerance was replaced with gastrointestinal problems (n = 121, Part D
of S2 Table). All RDCRN PMD cohort adults with kidney disease (n = 16) and all RDCRN
PMD cohort children with diabetes (n = 4) expressed willingness to participate in a clinical
trial (Part C of S2 Table).
Table 2. Demographic and other key characteristics of the RDCRN cohort (N = 290).
Adults (n = 169) Children (n = 121) p-value2
Female gender—% (n)1 75.2 (124) 47.0 (52) <.0001
Age, years: median (IQR) 48 (35–57) 12 (6–17) <.0001
Highest Education–% (n)
High school 12.5 (21) -
Some college 22.5 (38) -
College degree or equivalent 42.7 (72) -
Graduate degree 21.9 (37) -
No answer 0.6 (1) -
Known mutation–% (n) 0.4044
Yes 39.1 (66) 43.0 (52)
No 21.3 (36) 25.6 (31)
Maybe 38.5 (65) 31.4 (38)
No answer 1.2 (2) 0 (0)
Mutation–% (n) 0.0003
mtDNA 40.2 (68) 33.1 (40)
Nuclear DNA 4.7 (8) 20.7 (25)
Don’t know 49.1 (83) 43.8 (53)
No answer 5.9 (10) 2.5 (3)
Family History–% (n) 27.8 (47) 25.6 (31) 0.6782
Previous Experience % (n)
Participated in research study 30.2 (51) 34.7 (42) 0.3416
Participated in clinical trial 8.9 (15) 13.2 (16) 0.4618
Acquaintance participated in clinical trial 16.0 (27) 33.9 (41) 0.0018
1Cases with missing data are excluded for gender (4 adults and 10 children), and Previous Experience (maximum 4). No data are missing on other variables in the table.
2Comparison by two-sample t-test between Adult and Child groups is indicated by p-value.
https://doi.org/10.1371/journal.pone.0197513.t002
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Study drug characteristics
In the CHOP PMD cohort survey, subjects (n = 30) preferred if the study drug was a vitamin
(96.7%), natural supplement (96.7%), food (93.3%), antioxidant (90.0%) or a plant product
(83.3%) (S4 Table). Patients were less motivated to participate in a clinical trial if the study
drug had been used for other diseases but not in PMD (70.0%). Trials requiring subjects to
stop all of their medications (20.0%) or take a new drug (20.0%) were relative barriers to trial
participation. Ingesting a pill (83.3%) as the route of administration, either once (93.1%) or
twice (90.0%) a day, encouraged trial participation. An injection (46.7%), frequent (4 times
daily) treatment administration (63.3%), nurse administered medication (43.3%), in-hospital
administration (30.0%), and having an IV placed (48.1%) were discouraging factors to trial
participation. Having the study drug (93.3%), a comparable drug (96.6%), or a new but unre-
lated drug (82.8%) made widely available to study participants after trial completion were
encouraging factors. Experiencing symptom progression during the trial was a deterrent to
trial continuation (53.3%). The RDCRN validation PMD cohort (n = 290) results showed the
same pattern of motivating factors as were identified in the CHOP PMD cohort (n = 30) (S5
Table).
Subgroup analyses did not reveal significant differences.
Study design features
In the CHOP cohort, subjects (n = 30) were motivated to participate if the study helped multi-
ple (93.1%) or all (93.1%) symptoms, and the total study duration was no longer than one
month (85.7%) (S4 Table). The prospect of receiving only placebo (33.3%), crossover (48.1%),
double blind (29.6%) and randomized (37.0%) trial designs were relative barriers to trial par-
ticipation, as was concurrent enrollment in another clinical trial (25.9%). Monthly blood tests
(81.5%) were acceptable as were urine tests (80.8%), echocardiogram (85.2%), EKG (81.5%)
and ultrasound (81.5%). Travel within a city was also acceptable (88.9%). While an offer of
Fig 2. RDCRN mitochondrial disease subject validation cohort. A. Experienced Symptoms. Frequency of experienced symptoms as reported by the RDCRN self-
reported cohort revealed muscle weakness, chronic fatigue, exercise intolerance, imbalance, and gastrointestinal problems to be the top 5 common symptoms
(n = 290). B. Prioritized Symptoms for trial participation. The RDCRN cohort reported the same top 5 symptoms that would motivate trial participation (n = 290) as
seen in the CHOP cohort (Fig 1). C. Likely to participate if experienced symptom is targeted in a clinical trial. The RDCRN cohort reported muscle weakness,
chronic fatigue, exercise intolerance, diabetes and kidney disease as the most common experienced and desirable to treat symptoms in a clinical trial (n = 290).
https://doi.org/10.1371/journal.pone.0197513.g002
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cash (55.6%) or gift card (55.6%) were not incentives, lack of monetary reimbursement
(48.1%) was a deterrent.
The RDCRN survey revealed the same PMD subject preferences exist in the validation
cohort (S5 Table). Additionally, acceptable designs included no requirement to travel (82.1%)
or local travel (83.5%). Overnight stay (66.7%), domestic (61.0%) or international travel
(39.7%) were less favored. Out-of-pocket medical expenses (13.3%) or costs to participate
(18.9%) were major deterrents. Subjects were motivated to participate if the study was con-
ducted by an academic hospital (86.2%) or local doctor (87.8%), as compared to a pharmaceu-
tical company (64.2%). Participation in a later phase trial (Phase 3) was preferred, (81.2%) as
compared to a phase 1 (58.9%) trial.
Key study factors
Leading motivating factors and barriers incentives in the CHOP patient survey and RDCRN
validation cohort are summarized in S4 and S5 Tables. Key motivating factors included the
potential to cure (96.0%) and treat some disease symptoms (94.0%); as well as to prevent pro-
gression of disease (96.0%). The potential to benefit self (84.0%), family (84.0%), or other
affected patients (80.0%) were more encouraging factors than to aid science (68.0%). The pros-
pect of no existing alternative (84.0%) or affordable (84.0%) treatment options, or of no access
to study drug outside of the trial (80.0%) motivated trial participation. Access to free healthcare
(44.0%) was not an incentive, while potential out-of-pocket expenses (8.3%), potential to
worsen disease state (8.3%), transient major side effects (8.3%) and death from study participa-
tion (0%) were profound deterrents. The potential for transient minor side effects was a dis-
couraging factor (36.0%). Highlighting the importance of recruitment strategy, subjects were
more likely to enroll if they learned of the trial through a medical specialist (88.0%), another
trial participant (84.0%), a friend with mitochondrial disease (80.0%), phone call from the
study team (80.0%) or email from the North American Mitochondrial Disease Consortium
(NAMDC) (80.0%), as compared to from the general media. Genetic testing being performed
in the study (80.0%) was not a deterrent, particularly if results did not affect their health insur-
ance coverage (92.0%). This array of preferences was similarly reflected in the RDCRN valida-
tion cohort response (S5 Table). Surprisingly however, 7% of subjects were willing to accept
death as a potential risk of study participation.
Past experience in a research study and motivation to participate
We hypothesized that subjects with past experience in a research study or clinical trial (n = 98)
would remain motivated to participate in new treatment trials despite select study drug or
design factors that had been reported by the overall survey group as unfavorable. However,
logistic regression analysis of the RDCRN cohort data revealed that subjects with past research
experience were not more willing to participate if the study drug had not been used in people
before; if the medication was an injection; or if the study involved stopping one or all medica-
tions (S6 Table). Similarly, RDCRN cohort subjects were not more likely to participate if the
study was more than 1 year in duration; involved daily blood tests; assigned a placebo- only
arm; or involved double-blind or randomized design. Thus, prior study experience did not
predict improved tolerance for generally unfavorable study design characteristics.
Burden of disease and motivation to participate
We hypothesized that subjects with more severe disease would be willing to accept a higher
burden of trial participation. Analysis of treatment burden was conducted by creating a total
burden score of the i) Type of intervention (pill = 0, injection = 1); ii) Frequency of
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administration (below three = 0, three or more times a day = 1); and iii) Ease of administration
(self-administrated = 0, administrated by nurse/hospital = 1) (n = 263). For each subject, the
scores from each of these three dimensions were summed up to produce a total burden score
and ranked. Results indicated no correlation existed between disease severity and level of treat-
ment burden (S7 Table). Thus, higher disease severity did not predict acceptance of higher
clinical trial participation burden.
Discussion
The objective of this study was to identify motivating factors and barriers to clinical trial par-
ticipation in mitochondrial disease, as is essential to inform clinicians, researchers, advocacy
and regulatory partners, and pharmaceutical companies of PMD research subject needs and
expectations for clinical trial participation. Results of the discovery survey in the well-defined
CHOP PMD cohort were validated by analysis of a larger, self-identified PMD RDCRN cohort
survey, confirming the consistency of specific needs and preferences across a wide array of
subjects with PMD. Particularly striking was the discovery that subjects from both survey
PMD cohorts reported experiencing a mean of 16 major clinical symptoms. This finding
emphasizes the profound burden of PMD on patients, families, caregivers, and the health sys-
tem [31]. In both survey cohorts we also identified the most prevalent and prioritized symp-
toms for clinical trial participation to be muscle weakness, exercise intolerance, fatigue,
imbalance and gastrointestinal problems across all ages, as well as developmental delay in
children.
Identifying reliable clinical outcomes and reliable measure(s) to assess their response to
treatment in a clinical intervention trial represents the most fundamental steps in trial design.
Learning the patient perspective of their most prevalent and disabling symptom(s) that they
themselves prioritize for treatment is essential in PMDs that have such high phenotypic het-
erogeneity. This result is unique to PMD due to the multi-systemic nature of this disease, in
contrast to studies in other rare inherited disorders [32, 33]. Awareness of discrepancies in
physician-patient or physician-parent perceptions of disease burden need to be acknowledged
and considered in trial design [34]. Patient-centered care demands understanding patient’s
perspectives and working to meet their expectations [35, 36], which extends to clinical trials
that aim to evaluate new treatment approaches. To design successful clinical trials, considering
the patient rationale for clinical trial participation, expectations, and satisfaction will assure
that mitochondrial disease research endeavors directly match PMD patient priorities and
needs.
PMD patient disregard for study design elements that constitute a methodologically robust
interventional clinical trial such as placebo control, blinding, and randomization was apparent
in both surveys (S8 and S9 Tables and S1 Fig). While we postulated that PMD patients who
had more severe disease burden or past experience of research study and/or clinical trial par-
ticipation would be more amenable to accept these generally less favored trial design elements,
study results did not confirm this (S6 and S7 Tables). Therefore, these survey results under-
score the importance of educating PMD patients of the critical need to design and participate
in methodologically robust trial, as less rigorous studies cannot reliably inform clinical deci-
sion making [5]. We propose widespread, coordinated efforts that involve PMD patient advo-
cacy groups to organize community education sessions that clarify the components and need
for efficacious clinical trial design.
Recruitment strategy was highlighted as a key variable in this study, where direct physician
communication with PMD subjects was found most effective to motivate clinical trial partici-
pation. Recruitment for clinical trials in rare diseases can be aided by partnership with patient
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advocacy organizations and disease consortiums, particularly when a patient registry mecha-
nism exists [16, 37]. The NIH RDCRN and United Mitochondrial Disease Foundation
(UMDF) have patient-populated registries, respectively designed to recruit patients with all
rare and specifically mitochondrial diseases. In addition, NAMDC has established a clinician-
populated mitochondrial disease patient registry that provides the infrastructure to facilitate
and expedite research collaboration and clinical trials. Indeed, strong partnership between
advocacy organizations, researchers, patients, and families is a productive model that has been
demonstrated to lead to treatment interventions for several rare diseases [16, 38, 39].
A common theme between our study and prior investigations in other rare diseases is the
need to raise patient awareness of clinical trials, provide patient-centric solutions such as
reducing travel time and costs, and engage patients in the study design [40–42]. Similarly, the
duration and frequency of study visits, restrictions on concomitant drug use, and fear of clini-
cal deterioration during trial participation have also been identified as common barriers in
other rare diseases [40–42]. However, the inherent clinical complexity of PMD with highly var-
iable multi- system findings gives rise to the central finding of this study, which is the need to
understand the PMD patient perspective of incorporating their most prevalent and disabling
symptom(s) into the clinical trial design. Thus, our report meaningfully extends the literature
of patient motivation and barriers to participate in clinical trials.
A limitation of this study is the potential bias due to the response rate of 45% and 26% in
the CHOP discovery and RDCRN validation survey cohort populations. PMD is a burden-
some and highly morbid disease with frequent disease fluctuations triggered by acute stressors
such as illness. In addition, more than one family member is often affected and parents of
index cases may also be symptomatic. Indeed, the experience in our center with other surveys
conducted in our complex and highly morbid clinical cohort has been a similar response rate
of 30–45%. For these reasons, we consider the response rate of 46% attained in the CHOP
clinic cohort to be satisfactory. The CHOP clinic cohort had an established relationship with
the study investigators, which conceivably led to the higher response rate then the anon-
ymized, national RDCRN cohort. Despite this, however, the CHOP cohort study results were
closely replicated in the larger RDCRN cohort. Thus, it appears these 2 cohorts are representa-
tive of the broader PMD community. Recognizing relatively low response rate is a limiting fac-
tor, pursuing a larger, multi-center study of definite PMD patients to explore key findings
from our study would likely further enhance our understanding of PMD patient motivations
and barriers for trial participation.
In summary, this is the first study to report PMD patient preferences in terms of detailed
motivations and barriers to their participation in clinical intervention trials. Incorporating
patient prevalent symptoms, treatment needs, and trial expectations while improving educa-
tion efforts to emphasize the need for conducting scientifically rigorous clinical trials are cru-
cial factors in the development of clinically meaningful trials to develop efficacious therapies
for PMD.
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toms (maximum 0 [0.0%] for Adults and 0 [0.0%] for Children) are excluded. Lower denomi-
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